Free Trial
NASDAQ:NRXP

NRx Pharmaceuticals (NRXP) Stock Price, News & Analysis

NRx Pharmaceuticals logo
$1.68 -0.12 (-6.42%)
As of 01:07 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About NRx Pharmaceuticals Stock (NASDAQ:NRXP)

Key Stats

Today's Range
$1.58
$1.88
50-Day Range
$1.79
$3.55
52-Week Range
$1.10
$6.01
Volume
119,775 shs
Average Volume
451,658 shs
Market Capitalization
$28.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$28.25
Consensus Rating
Buy

Company Overview

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

Remove Ads

NRx Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
52nd Percentile Overall Score

NRXP MarketRank™: 

NRx Pharmaceuticals scored higher than 52% of companies evaluated by MarketBeat, and ranked 448th out of 901 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    NRx Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    NRx Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

  • Read more about NRx Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for NRx Pharmaceuticals are expected to grow in the coming year, from ($1.75) to ($0.08) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of NRx Pharmaceuticals is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of NRx Pharmaceuticals is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about NRx Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    7.34% of the float of NRx Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    NRx Pharmaceuticals has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in NRx Pharmaceuticals has recently decreased by 11.97%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    NRx Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    NRx Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.34% of the float of NRx Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    NRx Pharmaceuticals has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in NRx Pharmaceuticals has recently decreased by 11.97%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    NRx Pharmaceuticals has a news sentiment score of 0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for NRx Pharmaceuticals this week, compared to 2 articles on an average week.
  • Search Interest

    10 people have searched for NRXP on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.
  • MarketBeat Follows

    6 people have added NRx Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, NRx Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    19.00% of the stock of NRx Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 4.27% of the stock of NRx Pharmaceuticals is held by institutions.

  • Read more about NRx Pharmaceuticals' insider trading history.
Receive NRXP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NRx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

NRXP Stock News Headlines

BTIG Research Initiates Coverage on NRx Pharmaceuticals (NASDAQ:NRXP)
Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.
NRx Pharmaceuticals initiated with a Buy at BTIG
NRx Pharmaceuticals (NRXP) to Release Earnings on Friday
See More Headlines

NRXP Stock Analysis - Frequently Asked Questions

NRx Pharmaceuticals' stock was trading at $2.20 at the beginning of 2025. Since then, NRXP shares have decreased by 23.9% and is now trading at $1.6750.
View the best growth stocks for 2025 here
.

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) posted its quarterly earnings results on Friday, March, 14th. The company reported ($0.30) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by $0.10.

Shares of NRx Pharmaceuticals reverse split before market open on Tuesday, April 2nd 2024. The 1-10 reverse split was announced on Tuesday, April 2nd 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, April 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Shares of NRXP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that NRx Pharmaceuticals investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Adobe (ADBE), Meta Platforms (META), General Electric (GE) and Disc Medicine (IRON).

Company Calendar

Last Earnings
3/14/2025
Today
4/07/2025
Next Earnings (Estimated)
5/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:NRXP
Fax
N/A
Employees
2
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$28.25
High Stock Price Target
$45.00
Low Stock Price Target
$18.00
Potential Upside/Downside
+1,478.2%
Consensus Rating
Buy
Rating Score (0-4)
3.20
Research Coverage
5 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-30,150,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
($1.38) per share
Price / Book
-1.30

Miscellaneous

Free Float
12,717,000
Market Cap
$30.28 million
Optionable
Optionable
Beta
1.41
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:NRXP) was last updated on 4/7/2025 by MarketBeat.com Staff
From Our Partners